Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked faithfully but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last few shares. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire employment interview which I came away with an inadequate impression of the business.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology as well as connected intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug application endorsement ($5 million), as well as royalty payments of five % of net sales upon commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and many indications, it’s this individual remedy and a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple presentations in addition to multiple publications.

Can it all be smoke and mirrors? That is a question I have been asking myself from the very beginning of my interest in this particular organization. Judging by way of the multiples of a huge number of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *